Literature DB >> 9649138

Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.

R Abdel-Fattah1, C Challen, T R Griffiths, M C Robinson, D E Neal, J Lunec.   

Abstract

We have used microdissection of paraffin-embedded histological sections and polymerase chain reaction (PCR)-based direct DNA sequencing for 54 transitional cell carcinoma (TCC) of the bladder, to examine critically the association between TP53 nuclear accumulation determined by immunohistochemistry and the presence of TP53 mutations, and to examine their relationship to tumour stage and grade, as well as patient survival. There was a significant association between the presence of TP53-positive nuclei (> 10%) and a higher histological stage and grade (P = 0.0115, P = 0.0151 respectively; Fisher's exact). A significant association between TP53 gene mutations and TP53 nuclear reactivity in more than 10% of tumour cell nuclei was also observed (P = 0.0003; Fisher's exact). Mutations were detected in 18/54 (33%) cases together with the wild-type sequence when analysed from bulk frozen samples, with significant clustering of mutations in exons 7 and 8. The microdissection method distinguished more clearly between heterozygous and/or homozygous alterations of the TP53 tumour-suppressor gene, and clearly showed frequent accumulation of TP53 in the absence of mutations. When microdissecting immunonegative regions from the same paraffin sections, three out of ten samples showed the identical mutations detected in the immunopositive regions. There was a significant association between TP53 immunoreactivity in more than 50% of tumour cell nuclei and decreased survival among all patients (P = 0.0325; log-rank test). The patients with TP53 mutations showed a trend for a shorter survival period; however, the association was not statistically significant at the 95% confidence level (P = 0.132; log-rank test). In conclusion, our observations show that accumulation of TP53 occurs frequently in the absence of mutations, and that such accumulation is nevertheless associated with poor survival when it occurs in a high proportion (> 50%) of tumour cell nuclei.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649138      PMCID: PMC2150401          DOI: 10.1038/bjc.1998.371

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  A PCR-RFLP method for the detection of activated H-ras oncogene with a point mutation at codon 12 and 61.

Authors:  S J Hong; T Lee; Y S Park; K O Lee; B H Chung; S H Lee
Journal:  Yonsei Med J       Date:  1996-12       Impact factor: 2.759

2.  Frequency of active ras oncogenes in human bladder cancers associated with schistosomiasis.

Authors:  J Fujita; H Nakayama; H Onoue; J S Rhim; M N el-Bolkainy; A A el-Aaser; Y Kitamura
Journal:  Jpn J Cancer Res       Date:  1987-09

3.  Transcriptional activation of H-ras, K-ras and N-ras proto-oncogenes in human bladder tumors.

Authors:  D Vageli; H Kiaris; D Delakas; P Anezinis; A Cranidis; D A Spandidos
Journal:  Cancer Lett       Date:  1996-10-22       Impact factor: 8.679

4.  Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations.

Authors:  T Kawasaki; Y Tomita; V Bilim; M Takeda; K Takahashi; T Kumanishi
Journal:  Int J Cancer       Date:  1996-11-15       Impact factor: 7.396

5.  Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects.

Authors:  J A Vet; P P Bringuier; H E Schaafsma; J A Witjes; F M Debruyne; J A Schalken
Journal:  Lab Invest       Date:  1995-12       Impact factor: 5.662

6.  Accumulation of wild-type p53 in meningiomas.

Authors:  D W Ellison; J Lunec; P J Gallagher; P V Steart; E Jaros; K C Gatter
Journal:  Neuropathol Appl Neurobiol       Date:  1995-04       Impact factor: 8.090

7.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

Authors:  S Sjögren; M Inganäs; T Norberg; A Lindgren; H Nordgren; L Holmberg; J Bergh
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

8.  p53 mutations in human bladder cancer.

Authors:  W C Kusser; X Miao; B W Glickman; J M Friedland; N Rothman; G P Hemstreet; J Mellot; D C Swan; P A Schulte; R B Hayes
Journal:  Environ Mol Mutagen       Date:  1994       Impact factor: 3.216

9.  Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer.

Authors:  P K Lipponen; T J Liukkonen
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  10 in total

1.  Clinicopathological features and prognosis assessment of extranodal follicular dendritic cell sarcoma.

Authors:  Lan Li; Yong-Hong Shi; Zhi-Juan Guo; Tian Qiu; Lei Guo; Hong-Ying Yang; Xun Zhang; Xin-Ming Zhao; Qin Su
Journal:  World J Gastroenterol       Date:  2010-05-28       Impact factor: 5.742

2.  DNA copy number changes in Schistosoma-associated and non-Schistosoma-associated bladder cancer.

Authors:  W El-Rifai; D Kamel; M L Larramendy; S Shoman; Y Gad; S Baithun; M El-Awady; S Eissa; H Khaled; S Soloneski; M Sheaff; S Knuutila
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.

Authors:  Garrett M Dancik; Yuanbin Ru; Charles R Owens; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-10-19       Impact factor: 12.701

4.  p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.

Authors:  D A Tweddle; A J Malcolm; M Cole; A D Pearson; J Lunec
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 5.  p53 and chemosensitivity in bladder cancer.

Authors:  Hiroyuki Nishiyama; Jun Watanabe; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

6.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

7.  Lymphoepithelioma-like carcinoma of the bladder: three cases with clinicopathological and p53 protein expression study.

Authors:  Francisco Miguel Izquierdo-García; Fructuoso García-Díez; Isabel Fernández; Alberto Pérez-Rosado; Anabel Sáez; Dimas Suárez-Vilela; Rafael Guerreiro-González; Manuel Benéitez-Alvarez
Journal:  Virchows Arch       Date:  2004-04-06       Impact factor: 4.064

8.  Establishment and characterization of human bladder cancer cell lines BexBra1, BexBra2, and BexBra4.

Authors:  Camila B Piantino; Juliana M Sousa-Canavez; Victor Srougi; Fernanda Salvadori; Raphael Kato; Pedro Paulo R Ayres; Miguel Srougi; Luiz Heraldo Camara-Lopes; Gilka Jorge Figaro Gattás; Cintia Fridman; Fernanda de Toledo; Isaque Santana; Kátia Ramos Moreira Leite
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02       Impact factor: 2.416

9.  A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.

Authors:  K T Kelsey; T Hirao; A Schned; S Hirao; T Devi-Ashok; H H Nelson; A Andrew; M R Karagas
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

10.  Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.

Authors:  A W Hitchings; M Kumar; S Jordan; V Nargund; J Martin; D M Berney
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.